Novel Potent and Selective inhibitor of YEATS proteins

Novel selective bromodomain and extra-terminal domain (BET) protein family inhibitor (BETi ), inducing an ‘activated’ keratinocyte transcriptional profile with reversal of chronic wound biomarkers in human skin ex vivo

Novel potent PKCθ inhibitor

Specific inhibitor of the 25-hydroxyvitamin D(3)-24-hydroxylase (24-hydroxylase)

Novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R

The first non-peptide somatostatin sst(1) receptor antagonist

Novel nonpeptide bradykinin B1 receptor antagonist

Novel Syk inhibitor

Novel peptide deformylase (PDF) inhibitor; Antibacterial

Potent, orally active dipeptidyl peptidase (DPP)-IV inhibitor

Novel potent and selective p53-HDM2 inhibitor

Novel potent Jak2 type 1 inhibitor

Novel dual inhibitor of TORC1 and TORC2

Novel BCR-ABL Kinase Inhibitor

Novel potent and selective antagonist of somatostatin receptor subtype SST(3)

Novel Inhibitor of the Cysteine Protease Cathepsin K

Novel phosphodiesterase 4D (PDE4D) inhibitor

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel potent, orally bioavailable CXCR2 receptor antagonist

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs)

Potent and selective p53-MDM2 binding inhibitor

p53-MDM2 binding inhibitor; p-Glycoprotein (p-gp) transport substrate; Antitumer agent

Novel modulator of the NusB-NusE interaction

Novel Inhibitor of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity

Novel Potent Cell-Active Inhibitor of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition

Novel inhibitor of Helicobacter pylori , targeting H. pylori's respiratory complex I subunit NuoD

Nucleosidic antibiotic